|
Cabazitaxel, abiraterona y enzalutamida en cáncer de próstata metastásico resistente a la castración con fracaso a docetaxel [Cabazitaxel, abiraterone and enzalutamide in metastatic castration-resistant prostate cancer not responding to docetaxel] |
Oubiña M, García Martí S, Pichon-Riviere A, Augustovski F, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Oubiña M, García Martí S, Pichon-Riviere A, Augustovski F, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L. Cabazitaxel, abiraterona y enzalutamida en cáncer de próstata metastásico resistente a la castración con fracaso a docetaxel. [Cabazitaxel, abiraterone and enzalutamide in metastatic castration-resistant prostate cancer not responding to docetaxel] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 435. 2015 Authors' objectives To assess the available evidence on the efficacy, safety and coverage policy related aspects on the use of cabazitaxel, enzalutamide and abiraterone in metastatic castration-resistant prostate cancer not responding to docetaxel.
Prostate cancer is the most commonly diagnosed non-cutaneous malignant neoplasm in males.
At early stages, management includes surgery and radiotherapy, but if the disease is locally advanced or there are metastases, patients are treated with antiandrogen therapy. If there is progression after receiving treatment, it is known as metastatic castration-resistant prostate cancer (MCRPC).
Docetaxel is the standard therapy for MCRPC. For those patients who have presented progression after receiving docetaxel, drugs like cabazitaxel, abiraterone and enzalutamide have been developed as well as a technique based on leukapheresis called T-sipuleucel and a radiopharmaceutical called radium-223.
In this document, only antiandrogen or chemotherapy drugs will be assessed. The use of cabazitaxel, abiraterone and enzalutamide is proposed for the treatment of MCRPC, which progresses after receiving docetaxel, since it might increase overall survival.
Cabazitaxel is an antineoplastic drug from the taxane class. It is intravenously administered in six cycles. Abiraterone is an orally administered androgen inhibitor. Enzalutamide is an androgen receptor signal inhibitor which reduces the prostatic neoplastic cell proliferation and is orally administered.
Authors' conclusions The evidence found is of high quality. Treatment with cabazitaxel, enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer whose disease progressed after receiving docetaxel showed an increase in survival of approximately three to five months.
The health technology assessments and the clinical practice guidelines consulted recommend the use of the three drugs alike and the American health sponsors cover them in the reference population.
Indexing Status Subject indexing assigned by CRD MeSH Androstenols; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32015001165 Date abstract record published 17/11/2015 |
|
|
|